I see that some are pointing to DXB as a comparison, (I used to be in DXB, but made my money and got out) but DXB, while it has an awesome and important product, doesn't have:
phase 3 trial results;
FDA approval;
A product that is already selling in another jurisdiction;
strong sales results there;
a sales team and support network ready to go and primed for success.
DXB does have Nina, and she is brilliant.
BOT, as I have said before, will paddle its own canoe.
The CR may be an inconvenience for some, but it is seriously only a blip, but it is, as has been pointed out by others, an important step in maximising any return from any buyout that may appear on the horizon.
- Forums
- ASX - By Stock
- Ann: FDA Approves Sofdra
I see that some are pointing to DXB as a comparison, (I used to...
-
- There are more pages in this discussion • 269 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
0.010(2.56%) |
Mkt cap ! $707.4M |
Open | High | Low | Value | Volume |
39.5¢ | 40.0¢ | 39.5¢ | $572.4K | 1.448M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 63369 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 414259 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2075 | 0.395 |
5 | 65527 | 0.390 |
10 | 212671 | 0.385 |
10 | 427431 | 0.380 |
5 | 289816 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 495641 | 10 |
0.405 | 68105 | 3 |
0.410 | 167969 | 7 |
0.415 | 258680 | 6 |
0.420 | 607700 | 13 |
Last trade - 10.07am 02/10/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online